東曜藥業(01875.HK)向主要股東配股 淨集資4.71億元
東曜藥業-B(01875.HK)公佈,向主要股東晟德大藥廠及維梧蘇州基金分別配售3,375萬及約1.16億股,即合共配售近1.5億股,各佔公司擴大後股本約19.6%,每股配售價3.15元,與昨日(5月31日)收市價相同。
公司指,上述認購事項預期將改善集團的現金流,而不產生額外利息負擔;擴大集團的資本基礎,以支持集團長期發展。
東曜藥業預期,配售事項的所得款項淨額約爲4.71億元,擬將約35%用於持續建設全球研發中心及升級ADC製劑生產車間之資本開支;約25%用於完成TAA013(抗HER2 ADC,HER2+晚期乳腺癌)的III期臨牀試驗,以及TAE020(創新靶點ADC,急性骨髓性白血病)、TAC020(創新靶點mAb/重組蛋白,多種實體瘤)及管線中的其他在研藥物之正在進行及計劃進行的臨牀前及臨牀試驗;約20%用於擴大CDMO及CMO業務,並加強與國內外製藥公司的項目合作;約10%用於三款產品已獲上市批準的商業化生產、營銷及銷售活動,即TAB008、TOZ309及TOM218;約10%用於營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.